MCKHealthcare · Medical DistributionThe 18 Wall Street analysts covering McKesson Corp. hold a median 12-month price target of $1,000 — +14.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 86 of 100 as at 19 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores McKesson Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (99): The share price has been relatively steady.
Accruals (54): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (3): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on MCK, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +14.3% from it.
Of the 20 most recent actions, 6 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Sept 2026 | RBC Capital | Reiterates | Sector Perform | $845 |
| 19 Aug 2026 | Barclays | Maintains | Overweight | $925 → $1,000 |
| 19 Aug 2026 | Barclays | Maintains | Overweight | — |
| 19 Aug 2026 | RBC Capital | Initiates | Sector Perform | $845 |
| 19 Aug 2026 | RBC Capital | Initiates | Sector Perform | — |
| 11 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 11 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | $812 → $933 |
| 6 Aug 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 6 Aug 2026 | Evercore ISI Group | Maintains | Outperform | $860 → $1,000 |
| 6 Aug 2026 | TD Cowen | Maintains | Buy | — |
| 6 Aug 2026 | TD Cowen | Maintains | Buy | $989 → $1,006 |
| 6 Aug 2026 | UBS | Maintains | Buy | — |
| 6 Aug 2026 | UBS | Maintains | Buy | $1,050 → $1,080 |
| 24 July 2026 | Citigroup | Maintains | Buy | $945 → $1,000 |
| 24 July 2026 | Citigroup | Maintains | Buy | — |
| 21 July 2026 | TD Cowen | Maintains | Buy | $1,012 → $989 |
| 21 July 2026 | TD Cowen | Maintains | Buy | — |
| 10 June 2026 | Barclays | Maintains | Overweight | — |
| 10 June 2026 | Barclays | Maintains | Overweight | $1,050 → $925 |
| 14 May 2026 | Citigroup | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MCK appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 18 Sept 2026, McKesson Corp. returned +27.2% against +16.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 32% of US stocks
Cheaper than 90% of US stocks
Cheaper than 99% of US stocks
Cheaper than 21% of US stocks
Higher than 46% of US stocks
Higher than 20% of US stocks
Higher than 5% of US stocks
Higher than 47% of US stocks
Higher than 50% of US stocks
Higher than 3% of US stocks
Higher than 75% of US stocks
Higher than 7% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
McKesson Corp. has a market value of $102.0B and an enterprise value of $111.5B.
Revenue in the twelve months to 30 June 2026: $411.0B. The latest quarter grew 7.7% year on year.
Net income over the same four quarters: $5.3B, a 1.3% net margin.
Diluted earnings per share, trailing twelve months: $37.37.
Free cash flow in the twelve months to 30 June 2026: $6.1B, after $271.0M of capital spending.
McKesson Corp. spent $6.7B on share buybacks and $393.0M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 23.5×; forward P/E: 17.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.43%, paying out 9% of earnings.
McKesson Corp. employs 41,600 people — $9.9M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
| Company | Market cap | TKN rank |
|---|---|---|
| MCKMcKesson Corp. | $102.0B | 86 |
| CORCencora, Inc. | $59.9B | 70 |
| CAHCardinal Health, Inc. | $52.4B | 96 |
| HSICHenry Schein, Inc. | $9.7B | 81 |
| SYKStryker Corp.* | $105.2B | 73 |
| CVSCVS Health Corp.* | $112.8B | 88 |
| HCAHCA Healthcare, Inc.* | $92.6B | 67 |
* Nearest Healthcare names by size — few medical distribution companies of this scale trade in the US universe.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own McKesson Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
McKesson (MCK) shares closed at $887.29 in the latest trading session, down 1.36% from the prior day, a decline steeper than that of the broader market.
Why it matters — A MCK watcher would care because the stock underperformed the broader market in this session, marking a notable downward move worth tracking.
McKesson Corporation presented at the Morgan Stanley 24th Annual Global Healthcare Conference, with a transcript of the presentation published by Seeking Alpha. The item is a record of McKesson's remarks at the industry conference.
Why it matters — MCK watchers would care because the conference presentation provides insight into the company's strategy and outlook as shared directly with investors and analysts.
McKesson executives reported that the company's first-quarter performance supported a higher full-year earnings outlook, citing broad-based growth across its North American Pharmaceutical, Oncology & Multispecialty, and Prescription Technology Solutions businesses. The company is also pursuing oncology growth through a precision medicine deal.
Why it matters — A raised full-year outlook backed by broad-based growth and an expanding focus on oncology could signal strengthening momentum for MCK shareholders.
McKesson shares closed at $880.86, down 1.21% from the prior session, a larger decline than the broader market on that trading day.
Why it matters — A McKesson watcher would note the stock underperformed the general market for the day, which may signal relative weakness among investors.
AWKO Law LLP is investigating a data breach at McKesson that involved unauthorized access to sensitive information from 284 million patient records. McKesson disclosed the cybersecurity incident to the SEC on August 28, 2026.
Why it matters — A breach affecting a large volume of patient records could raise concerns for McKesson watchers about regulatory scrutiny, legal exposure, and reputational impact on the company's data security practices.
The 18 Wall Street analysts covering McKesson Corp. have a median 12-month price target of $1,000, with estimates ranging from $845 to $1,065. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 18 analysts covering McKesson Corp., 14 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks McKesson Corp. 86 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 19 Sept 2026, McKesson Corp. ranks 86 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (99 of 100).
No one can know that. What the data says: the median 12-month target from 18 analysts implies +14.3% from the last close, and Ticker Nerd's factor model ranks McKesson Corp. 86 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering McKesson Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MCK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $845 to $1,065 over the next 12 months.
McKesson Corp. returned +27.2% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
McKesson Corporation is a healthcare services company that supports the movement of medicines, medical supplies, and related services across the healthcare system. McKesson Corporation serves pharmacies, hospitals, long-term care facilities, clinics, and other care providers through its pharmaceutical distribution, medical-surgical, oncology, and prescription technology businesses.
The most recent item we track (Zacks Investment Research, 16 Sept 2026): "McKesson (MCK) Sees a More Significant Dip Than Broader Market: Some Facts to Know". McKesson (MCK) shares closed at $887.29 in the latest trading session, down 1.36% from the prior day, a decline steeper than that of the broader market.
McKesson Corporation is a healthcare services company that supports the movement of medicines, medical supplies, and related services across the healthcare system. McKesson Corporation serves pharmacies, hospitals, long-term care facilities, clinics, and other care providers through its pharmaceutical distribution, medical-surgical, oncology, and prescription technology businesses. Its North American Pharmaceutical operations handle branded, generic, specialty, biosimilar, and over-the-counter products, while its Prescription Technology Solutions segment helps connect patients, pharmacies, payers, and biopharma companies through software-enabled workflows. The company’s Medical-Surgical Solutions business supplies healthcare organizations with equipment, consumables, and logistics support. Based in Irving, Texas, McKesson Corporation plays a central role in healthcare infrastructure by helping customers manage access, distribution, and operational efficiency across the care continuum.
CEO Mr. Brian S. Tyler Ph.D. · 41,600 employees · United States · https://www.mckesson.com
